MetaCap

InMed Pharmaceuticals (INM) vs Traws Pharma (TRAW)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.

Summary

Traws Pharma is the larger company by market cap ($7.4 million vs $7.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

INM0.00%TRAW+0.27%
+0%+0%-0%
Oct 7, 20261 yearOct 8, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

INM versus TRAW key metrics
MetricINMTRAW
Share price$1.33$0.4803
Market cap$7.31M$7.38M
1-day change0.00%+0.27%
EPS (TTM)$-2.84$-1.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$2.40$3.27
52-week low$0.575$0.43
Distance from 52-week high-44.58%-85.31%
Analyst consensus—none
Avg. price target upside—+108.20%
Average volume914.23K569.02K
Shares outstanding5.49M15.37M
Employees64
SectorHealthcareHealthcare
IndustryDrug Manufacturers - Specialty & GenericBiotechnology

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About InMed Pharmaceuticals

INM stock →

InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States.

Healthcare · Drug Manufacturers - Specialty & Generic · 6 employees

About Traws Pharma

TRAW stock →

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.

Healthcare · Biotechnology · 4 employees

INM vs TRAW FAQ

Which is bigger, InMed Pharmaceuticals or Traws Pharma?

Traws Pharma (TRAW) is larger, with a market capitalization of $7.38M compared with $7.31M for InMed Pharmaceuticals (INM).

Are InMed Pharmaceuticals and Traws Pharma in the same industry?

Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for InMed Pharmaceuticals and Biotechnology for Traws Pharma.

More comparisons